The insider trading case involving Martha Stewart centered around her sale of shares in ImClone Systems, a biotechnology company focused on developing cancer treatments. The case unfolded at a time when ImClone's fortunes were tied to the approval of its experimental cancer drug, Erbitux, by the U.S. Food and Drug Administration (FDA). The subsequent events would have significant implications for Stewart's reputation and financial legacy.